Medicinal and edible traditional Chinese medicine compound with effect of treating simple obesity and non-alcoholic fatty liver and application of medicinal and edible traditional Chinese medicine compound

Abstract

The invention discloses a medicinal and edible traditional Chinese medicine compound for treating simple obesity rather than alcoholic fatty liver and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 to 20 parts of lotus leaves, 15 to 25 parts of semen cassiae, 8 to 18 parts of spica prunellae, 15 to 25 parts of fructus crataegi, 10 to 20 parts of flos lonicerae, 10 to 20 parts of semen persicae, 7 to 17 parts of rhizoma curcumae longae, 10 to 20 parts of radix angelicae sinensis, 2.5 to 12.5 parts of fructus mume and 1 to 6 parts of radix glycyrrhizae. The traditional Chinese medicine compound is composed of medicinal and edible raw materials and has the efficacy of losing weight and treating non-alcoholic fatty liver, and tests prove that the weight and body fat rate of diet-induced obese mice can be remarkably reduced by taking one dose of the traditional Chinese medicine compound per day, the blood sugar regulation capacity of organisms is improved, liver fatty degeneration is improved, and the non-alcoholic fatty liver disease is reduced. And the levels of serum liver enzyme and biochemical factors are reduced, so that the compound disclosed by the invention has good effects of losing weight and relieving fatty liver, and can be used for treating simple obesity and non-alcoholic fatty liver.

Description

Technical Field

[0001] The present invention relates to the field of traditional Chinese medicine, and in particular to a Chinese medicine compound having the function of treating simple obesity and non-alcoholic fatty liver and an application thereof. Background Art

[0002] With the rapid development of economy, the improvement of living standards and the change of dietary structure, obesity has become a common health problem and has gradually developed into a global epidemic. Obesity refers to a physiological state manifested by excessive accumulation of body fat, especially triglycerides. Due to the thickening of the fat layer, weight gain and bloated body shape are caused. Obesity is a group of metabolic syndromes caused by lipid metabolism disorders. When the body eats more calories than it consumes, the excess calories will be stored in the body in the form of fat. The amount exceeds the normal physiological needs and will evolve into obesity when it reaches the health threshold. Obesity has become a major public health problem. Data show that the obesity rate of the global population has increased year by year. Currently, there are more than 1.7 billion overweight adults and 300 million obese people. 68% of American adults aged 20 or above are overweight or obese, of which 34% are obese. The rising prevalence of obesity is the main driving force behind the increasing incidence and mortality of many metabolic diseases.

[0003] Non-alcoholic fatty liver disease (NAFLD) is a metabolic disease characterized by abnormal accumulation of triglycerides, excluding alcohol and other specific damage as causes of liver disease, and mainly manifested as fatty degeneration of the liver. The liver plays a vital role in the body's lipid metabolism. As the main site of lipid metabolism, the liver is involved in the entire process of lipid digestion, absorption, decomposition, synthesis, conversion and transportation. When exogenous lipids (fat ingested from food) affected by multiple factors are excessively consumed or lipid metabolism in the liver is dysregulated, fatty liver will be induced. Obesity is a potential factor that cannot be ignored in the occurrence of NAFLD, and it is also affected by multiple complex factors, such as genetics, environment, work and rest, intestinal flora, and comprehensive metabolism. When NAFLD cannot be controlled and treated, it will induce the occurrence of serious diseases such as non-alcoholic steatohepatitis (NASH), cirrhosis, and even liver cancer.

[0004] Simple obesity is a predisposing factor for non-alcoholic fatty liver disease, which often occurs with complications. Any drug that treats the disease alone cannot achieve stable and good results. Today, Western medicine focuses more on behavioral interventions and additional symptomatic treatments for obesity and NAFLD. Due to the complexity of the pathogenesis of the disease, the difficulty and challenge of drug development have increased. The instability of the efficacy of existing drugs has resulted in the lack of certification and use of specific drugs. At present, there are many types of drugs on the market that have clear effects on the treatment of two diseases, and the targeted mechanisms are complex. Most drugs can treat two diseases at the same time, which also confirms the fit of the disease characteristics of simple obesity and non-alcoholic fatty liver disease. However, although there are many drugs to choose from, the obvious adverse reactions of most drugs also make the application of drugs lose confidence. At present, there are not many drugs that have the effects of weight loss and treatment of non-alcoholic fatty liver disease. The main Western medicines are metformin, orlistat, rosiglitazone, etc., but they all have serious side effects, such as allergic reactions, cardiovascular risks, and hepatotoxicity.

[0005] Based on the complexity of simple obesity and NAFLD with multiple processes, multiple mechanisms, and multiple complications, the idea of ​​drug development based on only one or two targets is no longer suitable. Traditional Chinese medicine has the characteristics of multiple targets, multiple levels, and multiple angles in the prevention and treatment of diseases, and can provide new ideas for the treatment of metabolic diseases and metabolic complications represented by simple obesity and NAFLD. At the same time, traditional Chinese medicine is rich in variety, has fewer side effects, is safer and more reliable, and is expected to solve the problem of obvious toxic and side effects of Western medicine.

[0006] Food and medicine substances are an important part of the cultural resources of traditional Chinese medicine in my country. Based on the strategic background of Healthy China, the inheritance and development of the "food and medicine substances" culture has become a hot topic of widespread social concern. Nowadays, people's concept of disease has gradually shifted from treatment to prevention, and from relying solely on drugs to replaceable health foods. Food and medicine products generally have mild effects, taking into account health, nutrition and safety needs, are not prone to side effects, and have fewer adverse reactions when taken for a long time. The products are derived from daily ingredients and are easy to buy and take. Therefore, using the "food and medicine substances" resources to develop new health foods for the prevention and treatment of diseases is a new trend in the development of traditional Chinese medicine.

[0007] At present, the Chinese invention patent with the announcement number CN119405053A discloses a dehumidifying and weight-reducing composition based on the homology of medicine and food, and the composition comprises, by weight, 12-18% dried ginger, 8-12% wormwood, 8-12% cinnamon, 8-12% motherwort, 3-8% cloves, 3-8% prickly ash, and 3-8% pepper. The prescription has no clear effect on the treatment of fatty liver.

[0008] At present, the Chinese invention patent with the announcement number CN101095767 discloses a Chinese medicine compound preparation with a weight loss effect, characterized in that it includes the following raw materials in parts by weight: 10-15 parts of Radix Pseudostellariae, 10-15 parts of raw Astragalus, 8-12 parts of Radix Salviae Miltiorrhizae, 12-20 parts of dried lotus leaves, 12-20 parts of corn silk, 10-15 parts of raw hawthorn, 15-20 parts of Rhizoma Alismatis, 12-20 parts of raw Coix seeds, 10-15 parts of Plantago, 8-12 parts of stir-fried Atractylodes, 8-12 parts of Magnolia officinalis, 8-15 parts of Pericarpium Citri Reticulatae, and 6-10 parts of raw Licorice. However, the prescription has many components and high price, and the efficacy is unstable, and long-term use will burden liver and kidney functions.

[0009] At present, the Chinese invention patent with the announcement number CN119055732A discloses a Chinese medicine compound preparation with weight loss effect, which is composed of the following components by weight: 5-9% of bupleurum, 5-9% of fructus aurantii, 6-10% of salvia miltiorrhiza, 6-10% of oriental rhizome, 12-20% of patrinia herb, 12-20% of smilax china, 12-20% of sarmentosum, 12-20% of radish seeds, 6-10%. The compound preparation does not have the effect of treating non-alcoholic fatty liver disease at the same time, and the compound preparation contains non-medicinal and edible medicinal materials, so its safety and applicability are unstable and it is not suitable for long-term use.

[0010] Therefore, it is of great importance and value to develop Chinese herbal medicines and food compounds and their derivative products for the treatment of simple obesity and non-alcoholic fatty liver disease. Summary of the invention

[0011] The purpose of the present invention is to overcome the deficiencies of the prior art and to provide a Chinese medicinal compound for treating simple obesity and non-alcoholic fatty liver disease and a preparation method and application thereof.

[0012] To achieve the above purpose, the present invention designs a Chinese medicinal compound for treating simple obesity and non-alcoholic fatty liver disease. The raw materials of the Chinese medicinal compound include 10-20 parts of lotus leaves, 15-25 parts of cassia seeds, 8-18 parts of selfheal, 15-25 parts of hawthorn, 10-20 parts of honeysuckle, 10-20 parts of peach kernels, 7-17 parts of turmeric, 10-20 parts of angelica, 1-11 parts of black plums, and 1-8 parts of licorice in parts by weight.

[0013] Furthermore, the raw materials of the Chinese medicine compound include, by weight, 13-17 parts of lotus leaves, 18-22 parts of cassia seeds, 11-15 parts of selfheal, 18-22 parts of hawthorn, 13-17 parts of honeysuckle, 13-17 parts of peach kernels, 10-14 parts of turmeric, 13-17 parts of angelica, 4-8 parts of black plums, and 1-5 parts of licorice.

[0014] Furthermore, the raw materials of the Chinese medicine compound include, by weight, 15 parts of lotus leaves, 20 parts of cassia seeds, 13 parts of selfheal, 20 parts of hawthorn, 15 parts of honeysuckle, 15 parts of peach kernels, 12 parts of turmeric, 15 parts of angelica, 6 parts of black plums, and 3 parts of licorice.

[0015] The present invention also provides a method for preparing the above-mentioned Chinese medicinal compound for treating simple obesity and non-alcoholic fatty liver disease, comprising the following steps:

[0016] 1) Weigh lotus leaf, cassia seed, selfheal, hawthorn, honeysuckle, peach kernel, turmeric, angelica, black plum and liquorice according to the above weight ratio, soak them in water, heat them to boiling over high heat, turn to low heat and pour out the first decoction, then add warm water and heat to obtain the second decoction;

[0017] 2) Mixing the two obtained medicinal solutions to obtain a Chinese medicinal compound.

[0018] The present invention also provides an application of the above-mentioned Chinese medicinal compound for treating simple obesity and non-alcoholic fatty liver in a Chinese medicinal preparation for treating simple obesity and non-alcoholic fatty liver.

[0019] The present invention also provides a traditional Chinese medicine preparation, which comprises the traditional Chinese medicine compound and pharmaceutically acceptable excipients.

[0020] Furthermore, the Chinese medicine preparation is personalized for taste improvement, and its auxiliary materials can be any one or more of vitamin C, sorbitol, mannitol, xylitol, fructose, amino acids, meglumine, dextrin, magnesium stearate and sucrose.

[0021] Furthermore, the Chinese medicine preparation is any one of powder, oral liquid, granules, tablets, capsules, pills, syrup and ointment.

[0022] According to actual conditions, the Chinese herbal compound or Chinese herbal preparation can be concentrated to a concentration of 1g / mL for use.

[0023] The compound is mainly composed of heat-clearing drugs, and is supplemented with blood-activating and stasis-removing drugs such as peach kernel, turmeric, and angelica, which help defecation and bowel movement, black plum detoxifies the liver, and licorice harmonizes. Peach kernel and angelica have the effects of promoting blood circulation and removing blood stasis, moistening the intestines and relieving constipation. They are common drug pairs, and when combined with lotus leaves and hawthorn, they have the effects of promoting digestion, removing dampness, and regulating fat metabolism. Blood stasis and obstruction of collaterals are common causes of NAFLD. Peach kernel, salvia miltiorrhiza, safflower, angelica, etc. are common medicinal materials for blood-activating and stasis-removing prescriptions for the treatment of NAFLD. Honeysuckle mainly plays the role of clearing heat and detoxifying, and evacuating wind-heat. Honeysuckle contains compounds such as cyclopentane glycosides, chlorogenic acid, and caffeic acid, which have liver-protecting effects, liver-protecting and choleretic effects, and blood sugar-lowering effects, and can target PPARγ and FXR to participate in the regulation of fat metabolism. Turmeric has the effects of protecting the liver, choleretic, antibacterial, anti-inflammatory, and hypolipidemic effects. Its main component, curcumin, has more pharmacological activities and can effectively inhibit the synthesis of triglycerides. Black plum can promote the decomposition of bile, and finally play a role in enhancing the liver's detoxification function. Licorice is used as a guiding drug to play the effects of clearing away heat and purging fire, promoting blood circulation and removing blood stasis, and detoxifying. The above-mentioned drugs are coordinated.

[0024] Beneficial effects of the present invention:

[0025] 1. The Chinese medicinal compound of the present invention has the effects of reducing body weight and body fat percentage, improving the body's ability to regulate blood sugar, improving liver fatty degeneration, and reducing the levels of serum liver enzymes and biochemical factors, and can be used to treat simple obesity and non-alcoholic fatty liver.

[0026] 2. The medicinal materials used in the Chinese medicine compound of the present invention are low in cost and easy to purchase. The medicinal materials used in the prescription are all medicinal and edible, with high safety and applicability and no obvious side effects. The prescription has a short course of treatment and can show good efficacy for patients with hyperuricemia after taking the medicine for 15 days. The powder prepared by the prescription is fast in effect, easy to absorb, and simple to prepare. The granules prepared by the prescription are easy to store, have good palatability, and are convenient to take. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is a schematic diagram of the changes in body weight and food intake of mice in each group during the modeling stage;

[0028] In the figure, A is a schematic diagram of the weight changes of mice in each group, and B is a schematic diagram of the food intake changes of mice in each group;

[0029] Figure 2 This is a graph showing the effect of a Chinese herbal compound that has the effect of treating simple obesity and non-alcoholic fatty liver disease on the body weight and body fat percentage of obese mice;

[0030] In the figure, A is a schematic diagram of the weight of mice, B is a schematic diagram of the body fat percentage of mice, C is a schematic diagram of the change of the weight of mice, and D is a schematic diagram of the change of the body fat percentage of mice;

[0031] Figure 3This is a graph showing the effect of a Chinese herbal compound with the effect of treating simple obesity and non-alcoholic fatty liver disease on the fat weight of obese mice;

[0032] Figure 4 The changes in blood glucose levels and the area under the curve of a Chinese herbal compound that has the effect of treating simple obesity and non-alcoholic fatty liver disease in obese mice after oral administration of glucose;

[0033] In the figure, A is a schematic diagram of changes in blood glucose levels (IGTT), and B is a schematic diagram of the area under the blood glucose curve;

[0034] Figure 5 The effect of a Chinese herbal compound for treating simple obesity and non-alcoholic fatty liver disease on the body fat weight of obese mice

[0035] Figure 6 H&E section of mouse liver

[0036] Figure 7 This is a graph showing the effect of a Chinese herbal compound that has the effect of treating simple obesity and non-alcoholic fatty liver disease on liver-related biochemical indicators in the serum of obese mice;

[0037] In the figure, A is the ALB (albumin) index graph, B is the GLU (glucose) index graph, C is the TG (triglyceride) index graph, D is the TC (total cholesterol) index graph, E is the TP (total protein index graph), F is the ALT (alanine aminotransferase) index graph, G is the AST (aspartate aminotransferase) index graph, H is the ALP (serum alkaline phosphatase) index graph, and I is the γ-GT (γ-glutamyl transpeptidase) index graph. DETAILED DESCRIPTION

[0038] The present invention is further described in detail below in conjunction with specific embodiments so that those skilled in the art can understand.

[0039] Example 1

[0040] The raw material medicine composition of the traditional Chinese medicine compound for treating simple obesity and non-alcoholic fatty liver is: 15 parts of lotus leaf, 20 parts of cassia seed, 13 parts of selfheal, 20 parts of hawthorn, 15 parts of honeysuckle, 15 parts of peach kernel, 12 parts of turmeric, 15 parts of angelica, 6 parts of black plum and 3 parts of liquorice.

[0041] The above-mentioned Chinese medicinal materials were purchased from Hubei Zhihetang Pharmacy Co., Ltd. and used in subsequent experiments after accurate weighing.

[0042] The preparation method of the above-mentioned Chinese medicine compound comprises the following steps:

[0043] 1) Weigh 15g lotus leaf, 20g cassia seed, 13g selfheal, 20g hawthorn, 15g honeysuckle, 15g peach kernel, 12g turmeric, 15g angelica, 6g black plum, 3g liquorice. Soak in cold water (distilled water) for 20min, with the water surface 2-3cm above the medicine (or according to the material-liquid ratio of 1:6, w / v), heat to boiling over high heat, then heat over low heat for 25min (starting from boiling), pour out the first decoction, add appropriate amount of warm water and heat for 15min to obtain the second decoction.

[0044] 2) Mix the two obtained medicinal solutions to obtain a Chinese medicinal compound.

[0045] Example 2

[0046] The Chinese medicine compound 2 prepared in this example is basically the same as that in Example 1, except that:

[0047] The raw materials of the above-mentioned Chinese medicine compound 2 include 10 parts of lotus leaves, 15 parts of cassia seeds, 8 parts of selfheal, 15 parts of hawthorn, 10 parts of honeysuckle, 10 parts of peach kernels, 7 parts of turmeric, 10 parts of angelica, 1 part of black plum, and 1 part of licorice in parts by weight.

[0048] Example 3

[0049] The Chinese medicine compound 3 prepared in this example is basically the same as that in Example 1, except that:

[0050] The raw materials of the above-mentioned Chinese medicine compound 3 include 20 parts of lotus leaves, 25 parts of cassia seeds, 18 parts of selfheal, 25 parts of hawthorn, 20 parts of honeysuckle, 20 parts of peach kernels, 17 parts of turmeric, 20 parts of angelica, 11 parts of black plums, and 8 parts of licorice in parts by weight.

[0051] Example 4

[0052] The Chinese herbal compound decoctions 1-3 having the effect of treating simple obesity and non-alcoholic fatty liver disease correspond to the above-mentioned Chinese herbal compound decoctions 1-3 respectively.

[0053] In this embodiment, the Chinese herbal compound 1-3 is directly used as the Chinese herbal compound decoction 1-3. According to the actual situation, different auxiliary materials are added in the process of preparing the Chinese herbal compound decoction to improve the taste; wherein the auxiliary materials are citric acid and / or sucrose.

[0054] According to the verification effect of preparing Chinese medicine compound decoction 1 from the Chinese medicine compound 1 of Example 1:

[0055] 1. Verify the effectiveness of Chinese herbal compound decoction 1

[0056] (1) Experimental Materials

[0057] 1.1 Drugs:

[0058] The Chinese herbal compound decoction 1 was filtered with sterile gauze and concentrated to a relative crude drug concentration of 1 g / mL, which was a concentrated decoction. The high dose was two doses of the concentrated decoction, the medium dose was one dose of the concentrated decoction, and the low dose was half a dose of the concentrated decoction. Sodium carboxymethyl cellulose, orlistat (item number 96829-58-2, purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.), and Shenling Baizhu Decoction were filtered with sterile gauze and concentrated to a relative crude drug concentration of 1 g / mL.

[0059] 1.2 Animals:

[0060] 6-week-old SPF C57BL / 6 male mice (20±2g) were adapted to feeding in SPF animal rooms for 7 days, during which they were given normal drinking water and food. The ethics number is HZAUMO-2024-0256. All mice were kept in SPF animal rooms with appropriate temperature and humidity. 8 mice / cage, and mice were free to eat and drink. Since C57BL / 6 mice are very timid, environmental changes can easily cause stress reactions, which may lead to weight loss. Therefore, the feeding process should be kept as quiet as possible, and no disturbance or alarm should be made unless necessary.

[0061] 1.3 Feed and reagents:

[0062] High-fat feed (item number D12492, purchased from Beijing Keao Xieli Co., Ltd.), Co60 sterilized ordinary feed (purchased from Jiangsu Xietong Pharmaceutical Bioengineering Co., Ltd.), food-grade sucrose (purchased from Henan Wanbang Chemical Technology Co., Ltd.), and raw melon seeds (purchased from Shuyu Biotechnology Co., Ltd.).

[0063] (2) Experimental methods

[0064] 56 6-week-old SPF-grade C57BL / 6 male mice were randomly divided into 7 cages, 8 mice in each cage, and fed with the feeds corresponding to Table 1 during the period, with free access to water. Since C57BL / 6 mice are very timid, environmental changes can easily cause stress reactions, which may lead to weight loss. Therefore, the feeding process should be kept as quiet as possible, and no disturbance or alarm should be made unless necessary. Referring to the previous modeling experiment, transitional feed was added to the mice.

[0065] Modeling stage (0-42d): The food intake and body weight of mice were recorded every 7d, and the body fat percentage was detected after the mice were anesthetized on the 42nd day to estimate the modeling status.

[0066] Initial screening stage (42d-70d): From 42d to 70d, the corresponding drugs were gavaged daily according to Table 2. The original Control group mice were the Control1 group mice in Table 2. The HFD group mice were randomly divided into Model group, high, medium and low dose compound groups, orlistat group and Shenling Baizhu prescription group, with 8 mice in each cage. The food intake and body weight of the mice were recorded every 7d, and the body fat percentage was detected in the 10th week.

[0067] After the experiment, the mice were dissected and samples were collected and tested according to Table 3. The efficacy of each drug group was evaluated.

[0068] Table 1 Grouping of mice during modeling stage (0-42 days (d))

[0069] Group Name Feed composition Control Group Ordinary feed, sterile water HFD group High-fat diet, 10% fructose water, melon seeds

[0070] Table 2 Grouping of mice in the initial screening stage (42-72 days (d))

[0071]

[0072] Table 3 Detection indicators

[0073]

[0074] (3) Experimental results

[0075] 3.1 Modeling stage

[0076] Depend on Figure 1 It can be seen that before the high-fat and high-sugar diet induced the obese mouse model, there was no significant difference in the initial body weight between the normal group mice and the HFD group mice, which was concentrated at 19g. After the HFD group mice were fed with high-fat and high-sugar feed for 6 weeks (42 days), the weight gain rate of the HFD group mice was faster than that of the Control group mice, and statistical differences began to appear from the second week. This difference became more obvious over time, and the final weight of the mice was more than 6 times higher than that of the normal group ( Figure 1 A), and there was a significant difference compared with the normal group of mice. At the same time, the food intake of the HFD group mice also increased significantly ( Figure 1 B) This indicates that the diet-induced obesity mouse model was successfully established, as shown by a significant increase in body weight and food intake.

[0077] 3.2 Drug administration phase

[0078] 3.2.1 Obesity indicators

[0079] 3.2.1.1 Weight and body fat percentage

[0080] This experiment was conducted to study the effects of various drugs in preventing and improving obesity. Body weight and body fat percentage are key indicators for evaluating weight loss effects. The mice successfully modeled in 3.1 were divided into groups and given drugs. Figure 2 The results showed that the body weight and body fat percentage of mice in each group changed to varying degrees.

[0081] The results showed that the body weight and body fat percentage of mice in the Model group increased significantly compared with those in the Control1 group ( Figure 2A, B). After the 4-week experiment, the weight of mice in the groups receiving the high, medium and low compound drugs by gavage was lower than that in the model group, and it was statistically significant. The weight gain of the high-dose compound group and the medium-dose compound group was significantly lower than that of the model group, while the weight gain of the group receiving the low-dose compound drug by gavage was significantly lower than that of the model group ( Figure 2 C), and the medium-dose compound group and the low-dose compound group could significantly inhibit the increase of body fat percentage of model mice ( Figure 2 D), the effects of the medium-dose compound group in weight and fat reduction can even exceed those of the positive control drugs orlistat and Shenqin Baizhu decoction, indicating that the medium-dose compound group has a better effect in reducing the body weight and body fat rate of obese mice.

[0082] 3.2.1.2 Fat weight

[0083] The results of the measurement of mouse adipose tissue showed that ( Figure 3 ): There was no significant increase in the Model group compared with the Control1 group. Compared with the high-fat diet control group, the fat weight of mice receiving the three compound prescriptions was reduced, especially the medium-dose compound group, which showed statistical significance. The above results show that the medium-dose compound group can effectively reduce the fat accumulation of mice caused by a high-fat diet.

[0084] 3.2.1.3 Blood sugar

[0085] To evaluate the effect of the compound on improving glucose tolerance in obese mice. Figure 4 ), compared with the Control1 group, the blood glucose level and the area under the blood glucose curve (AUC) of the model group were both increased, while compared with the model group, the blood glucose levels of the three groups of mice treated with the high, medium and low doses of the compound group decreased. The analysis of AUC showed that the AUC of the treatment group was significantly reduced, among which the AUC of the medium dose group was the lowest, exceeding that of the orlistat group. The above data show that the compound group can effectively alleviate the glucose metabolism disorder caused by obesity, and the medium dose is the optimal dose of the compound.

[0086] 3.2.2 Fatty liver indicators

[0087] 3.2.2.1 Liver index

[0088] To explore the effect of the compound on liver tissue, the results show that ( Figure 5 ), the liver index of the Model group increased significantly, indicating that high-fat modeling led to an increase in the overall proportion of the mouse liver. The compound can reduce the increase in liver mass induced by a high-fat diet, among which the effect of the medium-dose compound group was the most significant, indicating that the medium-dose compound group can reduce the liver index and protect liver health.

[0089] 3.2.2.2 HE staining of liver tissue

[0090] HE staining results of liver tissue sections showed ( Figure 6 ), the cells in the liver lobules of the Model group were disordered, the cord structure was destroyed, and the cell edges were blurred. Some cells underwent fatty degeneration, which was manifested by the appearance of lipid droplets of varying sizes in the cells, and inflammatory cell infiltration in the liver sinusoids. The liver tissue lesions of mice in the medium-dose compound group were improved, the liver cord structure was more complete than that of the Model group, the cell structure was clear, and the migration and infiltration of inflammatory cells were reduced.

[0091] 3.2.2.3 Serum biochemistry

[0092] In order to explore the effect of the compound on serum biochemical factors, the levels of ALB, GLU, TG, TC, TP, ALT, AST, ALP and γ-GT, which are common biochemical indices for assessing liver health, were detected in mouse serum. The results show ( Figure 7 ), high-fat diet does not affect the levels of ALB, GLU, TC, TP, AST, ALP and γ-GT in the serum of mice, but can significantly increase the levels of ALT and TG in the serum. After 4 consecutive weeks of treatment, the levels of ALT and TG in the serum of mice in the high, medium and low dose compound groups were significantly lower than those in the high-fat diet control group, and the other indicators were not significantly affected. Among them, the medium dose compound group had the best effect, which was more significant than the positive drug orlistat group and the Shenling Baizhu group. At the same time, the medium dose compound group given by intragastric administration can also reduce the ALP level in the serum of mice, and there is a statistical difference compared with the Model group.

[0093] The above results show that the medium-dose compound group can significantly reduce the levels of ALT, ALP and TG in the serum of obese mice and effectively improve liver health.

[0094] Although the above embodiments have been described in detail, they are only a part of the embodiments of the present invention, not all of them. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all belong to the protection scope of the present invention.

Claims

1. A Chinese medicinal compound having both medicinal and edible properties for treating simple obesity and non-alcoholic fatty liver disease, characterized in that: The raw materials of the Chinese medicine compound are all of medicinal and edible origin, and include, by weight, 10-20 parts of lotus leaf, 15-25 parts of cassia seed, 8-18 parts of selfheal, 15-25 parts of hawthorn, 10-20 parts of honeysuckle, 10-20 parts of peach kernel, 7-17 parts of turmeric, 10-20 parts of angelica, 1-11 parts of black plum and 1-8 parts of liquorice.

2. The Chinese medicinal compound for treating simple obesity and non-alcoholic fatty liver disease according to claim 1, characterized in that: The raw materials of the traditional Chinese medicine compound include 13-17 parts of lotus leaves, 18-22 parts of cassia seeds, 11-15 parts of selfheal, 18-22 parts of hawthorn, 13-17 parts of honeysuckle, 13-17 parts of peach kernels, 10-14 parts of turmeric, 13-17 parts of angelica, 4-8 parts of black plums and 1-5 parts of liquorice in parts by weight.

3. The Chinese medicinal compound for treating simple obesity and non-alcoholic fatty liver disease according to claim 2, characterized in that: The raw materials of the traditional Chinese medicine compound include 15 parts of lotus leaf, 20 parts of cassia seed, 13 parts of selfheal, 20 parts of hawthorn, 15 parts of honeysuckle, 15 parts of peach kernel, 12 parts of turmeric, 15 parts of angelica, 6 parts of black plum and 3 parts of liquorice by weight.

4. A method for preparing the Chinese medicinal compound for treating simple obesity and non-alcoholic fatty liver disease according to any one of claims 1 to 3, characterized in that: The following steps are involved: 1) Weigh lotus leaf, cassia seed, selfheal, hawthorn honeysuckle, peach kernel, turmeric, angelica and black plum according to the above weight ratio, soak them in water, heat to boiling over high heat, turn to low heat and pour out the first decoction, then add warm water to obtain the second decoction; 2) Mixing the two obtained medicinal solutions to obtain a Chinese medicinal compound.

5. Use of the Chinese medicinal compound of any one of claims 1 to 3 in the preparation of Chinese medicinal preparations for weight loss and treatment of non-alcoholic fatty liver disease.

6. A Chinese medicine preparation, characterized in that: The Chinese medicine preparation comprises the Chinese medicine compound according to any one of claims 1 to 3 and pharmaceutically acceptable excipients.

7. The Chinese medicine preparation according to claim 6, characterized in that: The auxiliary material can be any one or more of vitamin C, sorbitol, mannitol, xylitol, fructose, amino acids, meglumine, dextrin, magnesium stearate and sucrose.

8. The Chinese medicine preparation according to claim 6 or 7, characterized in that: The Chinese medicine preparation is any one of powder, oral liquid, granule, tablet, capsule, pill, syrup and ointment.

Images